



Herpes Zoster Work Group Activity Update

ACIP Meeting

Feb 22, 2017

Edward Belongia, MD

ACIP Chair, Zoster Working Group

Center for Clinical Epidemiology & Population Health

Marshfield Clinic Research Foundation

2017 Herpes Zoster Work Group

| | | |
|----------------------------|------------------------------------|---------|
| ACIP Members | Edward Belongia, MD (Chair) | |
| | Kelly Moore | |
| Ex Officio Members | Paula Agger, MD, MPH | FDA |
| | Jeffrey Cohen, MD | NIH |
| | Jeffrey Kelman, MD | CMS |
| Liaison Representatives | Jeffrey Duchin, MD | NACCHO |
| | Mary Pat Friedlander, MD | AAFP |
| | Adam Welch, PharmD | APhA |
| | William Schaffner, MD | NFID |
| | Kenneth Schmader, MD | AGS |
| | Sandra Fryhofer, MD | AMA/ACP |
| | Kathy Neuzil, MD, MPH | IDSA |
| | Mark Netoskie, MD, MBA | AHIP |
| | Lynn Bahta, RN, PHN | AIM |

| |
|----------------------------|
| Invited Consultants |
| Robin Avery, MD |
| Al Benson, MD |
| Paul Cieslak, MD |
| Jeffrey Curtis, MD, MPH |
| Samuel Katz, MD |
| Vicki Morrison, MD |
| Steven Pergam, MD |
| Lisa Prosser, PhD |

| |
|----------------------|
| CDC Liaison |
| Rafael Harpaz, MD |
| Kathleen Dooling, MD |

Terms of Reference of the Herpes Zoster Work Group

The objective of the Herpes Zoster Work Group is to develop evidence-informed vaccine policy for the use of herpes zoster vaccines. The Work Group will:

- Consider vaccine and programmatic performance of currently licensed vaccine (Zostavax)
- Consider the efficacy, safety and duration of protection of herpes zoster/subunit vaccine that is currently in review at FDA
- Identify programmatic options for both vaccines that incorporate cost effectiveness analyses and impact on disease burden

Recent Work Group Activities

- Reached consensus on important and critical outcomes to consider pertaining to vaccination for herpes zoster
- Received presentations by manufactures and researchers on safety and immunogenicity of herpes zoster vaccines
- Considered the body of evidence supporting HZ/su

Presentations to ACIP

■ October 2016

- Herpes zoster epidemiology & Zostavax performance and coverage
- Phase III efficacy study of HZ/su (ZOE-50 & ZOE-70)

■ Feb 2017

- Safety Summary of HZ/su (GSK)
- GRADE of HZ/su & Considerations for policy (CDC)

■ June 2017

- Cost effectiveness analysis
- Zostavax GRADE
- Considerations for policy

■ October 2017

- Vote

Acknowledgements

- ACIP Herpes Zoster Work Group
- CDC contributors: Jessica Allen, Carolyn Bridges, Amanda Cohn, Angela Guo, Theresa Harrington, David Kim, Adriana Lopez, Mona Marin, Karen Mason, Ismael Ortega-Sanchez, Manisha Patel, Aparna Ramakrishnan, Ray Strikas, Candice Swartwood, Chengbin Wang